



SUVEN Life Sciences

Communication to investors

Mar 2016

27-May-16

2015-16 Q4 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter 4 – Mar 2016



- Growth in revenue 49.21%
- Growth in PAT 82.23%
- Growth in EBIDTA 65.58%
- Growth in Pre-R&D EBIDTA 46.54%
- Increase in R&D costs 10.63%
- R&D cost on revenue 9.66%

FINANCIAL QUICK VIEW

Year ending – Mar 2016



- Growth in revenue -2.00%
- Growth in PAT -12.67%
- Growth in EBIDTA -15.14%
- Growth in Pre-R&D EBIDTA -8.64%
- Increase in R&D costs 10.51%
- R&D cost on revenue 12.13%

MAJOR PROFITABILITY RATIOS







	Q4 Mar 16	YE Mar 16
PAT to Income	18.58%	18.30%
EBIDTA to Income	27.25%	27.48%
Cash Flow to Income	21.34%	21.53%
Pre-R&D EBITDA to Income	36.91%	39.62%



Q4 to Q3 COMPARISON


Current quarter to previous quarter





INCOME COMPARISON

Year on year




27-May-16

2015-16 Q4 results



PROFIT COMPARISON

Year on year




27-May-16

2015-16 Q4 results



EBIDTA COMPARISON

Year on year




27-May-16

2015-16 Q4 results



R & D – EXPENDITURE

Year on year




27-May-16

2015-16 Q4 results



PRE-R&D EBIDTA

Year on year




27-May-16

2015-16 Q4 results



PRE-R&D CASHFLOW

Year on year



27-May-16

2015-16 Q4 results



Financial Snapshot

All figures are in INR Million, other than ratios and EPS

	Q4 Cur qtr	Q3 Pre qtr	Growth %	PreYrqtr	Growth %	2015-16	2015-16	2014-15	Growth %
						Standalone	Consolidated		
Income	1,737.93	1,164.74	49.21%	1,144.73	51.82%	5,188.73	5,188.73	5,294.36	-2.00%
Pre-R&D EBITDA	641.46	437.75	46.54%	398.98	60.77%	2,055.55	2,055.06	2,250.02	-8.64%
Pre-R&D EBITDA Margin	36.91%	37.58%		34.85%		39.62%	39.61%	42.50%	
EBITDA	473.64	286.06	65.58%	263.05	80.05%	1,426.04	1,143.78	1,680.40	-15.14%
EBITDA Margin	27.25%	24.56%		22.98%		27.48%	22.04%	31.74%	
EBIT	425.65	240.86	76.72%	238.58	78.41%	1,258.83	976.57	1,562.64	-19.44%
EBIT Margin	24.49%	20.68%		20.84%		24.26%	18.82%	29.52%	
Financing costs	15.61	15.39		12.10		54.17	54.21	47.09	
Taxes	87.14	48.28		57.00		254.98	254.98	428.04	
Net Profit after tax	322.90	177.19	82.23%	169.49	90.51%	949.69	667.39	1,087.50	-12.67%
NP Margin	18.58%	15.21%		14.81%		18.30%	12.86%	20.54%	
EPS (basic & diluted not annualised)	2.54	1.39		1.41		7.46	5.24	9.04	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28	127.28	127.28	
Depreciation	47.98	45.20		24.47		167.20	167.20	117.76	
R&D expenses	167.82	151.70	10.63%	135.93	23.46%	629.51	911.28	569.63	10.51%

On consolidation of the accounts of Suven, Inc., USA, the wholly owned subsidiary, the PAT reduced to INR 667 Mn and expenditure on R&D increased to INR 911 Mn..

27-May-16

2015-16 Q4 results



News Release

- SUVN-502 Phase 2A clinical trial, indicated for patients with moderate Alzheimer's initiated in 58 investigator sites in USA.
- SUVN-D4010 Phase 1 clinical trial initiated in USA and ongoing.
- During the period Suven secures 9 product patents covering Australia, Canada, China, Eurasia, Hong Kong, Israel and USA.
- Suven presented in Bio-Europe Spring 2016 held in Stockholm, Sweden in April 2016.
- Suven presented in investors meeting in London, Honk Kong and Singapore in March 2016.